TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Impact of Metformin on In Vitro Fertilization Outcomes in Overweight and Obese Polycystic Ovary Syndrome Women; A Quasi Experimental Study
Brief Summary: RCT to investigate whether metformin co-treatment would improve IVF outcomes in overweight and obese women with PCOS.


Options:
A: Inclusion Criteria:

* Fulfilling Rotterdam criteria for PCOS
* Infertility more than 1 year
* First or second cycle of IVF/ICSI treatment
* Age below 38 years at inclusion
* BMI below 28 kg/m3 at inclusion
* Willing to be randomised to 4 months metformin or placebo
* Signed written informed consent

Exclusion Criteria:

* Not suitable for starting dose 112.5 IE
* Basal FSH above 10 IU/L
* Known renal disease or s-creatinine above 110 umol/L
* Known liver disease or s-ALAT above 80 IU/L
* Known alcoholism or drug abuse
* Known diabetes mellitus or fasting plasma glucose above 7 mmol/L
* Corticosteroid treatment (oral)
* Treatment with cimetidine, anticoagulants, erythromycin or other macrolides
* Hyperprolactinemia (PRL above 700 mIU/L)
* Abnormal thyroid function tests
* Known congenital adrenal hyperplasia
* Androgen secreting tumours
* Cushing syndrome
* Metformin treatment within the last one month prior to screening
* Unfit to participate for any other reason
B: Inclusion Criteria:

* PCOS
* Prognosis for poor response
* Infertility

Exclusion Criteria:

* Male factor infertility
* Tubal infertility
C: Inclusion Criteria:

* The inclusion criteria restricted the patients to 39 years old with basal FSH \< 10 IU/ml and normal TSH and prolacin.

Exclusion Criteria:

* Exclusion criteria were diabetes mellitus (excluded by GTT), renal or liver disease, associated male factor, documented tubal factor or pelvic adhesions, elevated 17 alfa hydroxyprogesterone level and FSH ≥10 IU/ml. We also excluded the women who started program or medications to reduce their weight and those who their partner has abnormal semen parameters according to the world health organization parameters (WHO, 2010)
D: Inclusion Criteria:

* History of one previous cancelled cycle for high-risk of OHSS, or history of moderate/severe OHSS during their previous IVF cycle
* Infertility
* Polycystic ovary syndrome (PCOS)
* insulin resistance
* hyperandrogenism

Exclusion Criteria:

* BMI\>30 kg/m2
* age \>35 years
* FSH\>9UI/L

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Latinas LEarning About Density (LLEAD Study)
Brief Summary: This study will examine behavioral and psychological outcomes of breast density notification using a 3-group randomized design comparing usual written notification to two educationally enhanced approaches.


Options:
A: Inclusion Criteria:

* Spanish-speaking adults ≥ 55 years of age
* ≥ 2 chronic illnesses determined by ICD-9 codes
* ≥ 2 visits with an outpatient primary care clinician at San Francisco General hospital in the past year
* ≥ 2 additional outpatient/inpatient visits to San Francisco General Hospital in the past year

Exclusion Criteria:

* Deaf, blind, demented or psychotic as determined by ICD-9 codes
* Too mentally or physically ill to participate as determined by their clinicians
* Moderate or severe cognitive impairment as determined by the Short Portable Mental Status Questionnaire (SPMSQ), and mild cognitive impairment by the SPMSQ plus an abnormal Mini-Cog (scores minimally affected by education/ethnicity)
* Self-reported poor vision and inability to see the words on a newspaper
* Lack of a telephone (for follow-up)
* Traveling or moving out of the area for ≥3 months during the study follow-up period.
B: Inclusion Criteria:

* be a minimum of 18 years of age
* be of Latino descent
* report limited English language proficiency
* meet current MDD criteria
* have completed the 4th grade or higher either in their country of origin or in the US
* not have current substance abuse or dependence
* have no Bipolar or Psychotic Disorders
* not be currently receiving psychotherapy
* if currently taking antidepressants, demonstrate pharmacological stability as indicated by 3 or more consecutive months of use.
C: Inclusion Criteria:

* Female
* Attending screening mammography at Mountain Park Health Center
* Speak English or Spanish

Exclusion Criteria:

* Male
* Current diagnosis of breast cancer
D: Inclusion Criteria:

* Self-identifies as a first-generation Korean American
* Systolic blood pressure greater than 140 mm Hg and/or diastolic blood pressure greater than 90 mm Hg OR currently on medication to treat high blood pressure
* Access to a telephone

Exclusion Criteria:

* Current participation in another clinical trial
* Acute and/or terminal medical condition that would make study participation difficult (e.g., terminal cancer, acute heart attack)
* Psychiatric diagnosis that would make study participation difficult (e.g., schizophrenia, cognitive impairment)

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: N/A
Brief Summary: Recent studies showed the benefits of early initiation and advancement enteral feeds with daily increments in preterm infants on decreasing invasive infections and early achievement of full enteral feedings. But the data on enteral feeds of extremely low birthweight infants are limited. Preterm infants especially those \<1250 gr birthweight are at increased risk of developing feeding intolerance and necrotizing enterocolitis (NEC) and so the initiation and the rate of increments of enteral feeds are usually uncertain issues for neonatologists.


Options:
A: Inclusion Criteria:

* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days

Exclusion Criteria:

* Chromosomal anomalies.
* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)
* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention
* Parental refusal
* Prior enrollment into a conflicting clinical trial
B: Inclusion Criteria:

* Infants with birth weight less than 1500g

Exclusion Criteria:

* Sever bacteremia
* Congenital anomaly
* Not suitable for the trial defined by an attending neonatologist
C: Inclusion Criteria:

* gestational age≤32 weeks and birthweight ≤1250 gr, and \<48 hours postnatal age

Exclusion Criteria:

* Major congenital and/or chromosomal anomaly, Cyanotic congenital heart disease, Asphyxiated birth with pH \<7.0 and base deficit ≥16mmol/l Severe cardiopulmonary compromise or multiorgan failure Twin-twin transfusion, Those died in postnatal 5 days of age
D: Inclusion Criteria:

* Preterm infants ≦ 34 weeks gestational age and birth weight below 1500 gm and who survive to NICU are eligible for the trial.

Exclusion Criteria:

* severe asphyxia (stage III),
* fetal chromosomal anomalies,
* cyanotic congenital heart disease,
* congenital intestinal atresia, gastroschisis, omphalocele, active upper gastric intestinal bleeding,
* lacking/refused of parental consent,
* those who are fasted for \>3 weeks during the study period.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Mass Drug Administration of Monthly DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique
Brief Summary: In line with the global and regional efforts towards malaria elimination, a five year program was established to assist the NMCP in adopting targeted evidence-based elimination plans through a 'learn by doing' strategy. The project aims to generate knowledge as data is generated to inform the programmatic aspects of the elimination plan, most importantly how to clear malaria parasites from the asymptomatic reservoir.


Options:
A: Inclusion Criteria:

* anyone not excluded and consenting

Exclusion Criteria:

* contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin
* anyone seriously ill
* currently taking antimalarial medicines
* allergy to artemisinin drugs
* pregnant women in first trimester
* children under 3 months of age
* reported heart condition
B: Inclusion Criteria:

* Permanent or temporary resident of study Shehias (i.e., persons who stayed in the selected household the night before the interview)
* Provision of informed consent (refusal must be recorded)
* Age \>6 months

Exclusion Criteria:

* Women pregnant in first trimester (assessed by a specific set of questions designed to exclude pregnancy)
* Severe disease that requires immediate referral to health facility or hospital
* Concurrent antimalarial treatment at time of MDA or during the last 14 days
* Inability to take oral medication

Additional exclusion criteria for treatment with SLD Primaquine:

* Pregnancy (all trimesters, assessed by a specific set of questions designed to exclude pregnancy)
* Women breast feeding infants aged \< 6months
C: Inclusion Criteria:

* Individuals who consent to participate in the study
* Residents in the study area
* Older than 6 months of age (or weighing more than 5Kg)
* Women in the second or third trimester who are not on IPTp

Exclusion Criteria:

* Individuals who do not consent to participate in the study
* Younger than 6 months of age (or weighing more than 5Kg)
* Women in the first trimester of pregnancy
* Severely ill individuals
* Individuals on contra-indicated medication
D: Inclusion Criteria:

* permanent resident of the research area
* age \>1 years

Exclusion Criteria:

* severe anemia
* pregnancy

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Women's Heart Attack Research Program: Stress Ancillary Study; Telephone-Based Stress Management for Women With Myocardial Infarction
Brief Summary: The Women's HARP study is a multi-center study focusing on women with clinical presentation of myocardial infarction (MI). Women will complete stress questionnaires following presentation to the medical center with elevated cardiac enzymes and abnormal electrocardiograms (ECGs). 2 months following MI, participants will be screened for the Stress Ancillary Study and enrolled if an elevated level of perceived stress is reported. After completing baseline assessments, participants will be randomized to Enhanced Usual Care (EUC) or stress management for 8 weeks. Participants will be followed for 6 months.


Options:
A: Inclusion Criteria:

* Diabetes Type 2
* Albuminuria
* Age 30-70

Exclusion Criteria:

* Diabetes duration \< 3 years
* Preexisting non-diabetic kidney
* Psychiatric disorders
* Alcohol or drug abuse
* Malignant tumors or hematologic disorders
* Heart failure NYHA III-IV
* Acute coronary syndrome
B: Inclusion Criteria:

* BMI\>30;
* Written and informed consent to participate; 4) being technology friendly to use wearable devices.

Exclusion Criteria:

* other psychiatric disturbances (diagnosed according to DSM 5 criteria);
* other medical conditions not related to obesity that could compromise participation at the study.
C: Inclusion Criteria:

* Acute ischemic symptoms compatible with diagnosis of MI, such as chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms
* Objective evidence of MI (either or both of the following):

  * Elevation of troponin to above the laboratory upper limit of normal
  * ST segment elevation of ≥1mm on 2 contiguous ECG leads
* Willing to provide informed consent and comply with all aspects of the protocol
* Age ≥ 21 years
* Female sex
* PSS-4 score ≥6 at 2 month follow up visit after MI

Exclusion Criteria:

* Alternate explanation for troponin elevation, such as hypertensive urgency, acute exacerbation of heart failure, chronic elevation due to kidney disease, pulmonary embolism, cardiac trauma.
* Moderately severe or severe depressive symptoms (PHQ-9 ≥ 15)
* Active suicidal ideation (PHQ-9 item #9 or otherwise reported during screening)
* History of or current diagnosis of psychosis (EHR review)
* Significant cognitive impairment (EHR review or evident during screening)
* Current participation in another behavioral clinical trial.
D: Inclusion Criteria:

African American men and women with documented coronary heart disease defined a coronary angiogram demonstrating the presence of one more coronary arteries with \> or = 50% stenosis.

Exclusion Criteria:

acute MI, stroke or coronary revascularization within the previous three months; symptomatic heart failure with EF \< 20%; dementia or other cognitive impairment determined clinically; and non-cardiac life threatening illness.

-

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Chlorhexidine Gluconate vs Povidone-Iodine Vaginal Cleansing Solution Prior to Cesarean Delivery: A Randomized Comparator Controlled Trial
Brief Summary: Endometritis, an infection of the uterus in the postpartum period, has been shown to complicate the postoperative course of a cesarean delivery in 6% to 27% of cases. Vaginal cleansing prior to cesarean delivery has been shown to minimize the presence of micro-organisms and risk of infection. Although povidone-iodine is the most commonly used anti-septic for surgical preparation of the vagina, it is not an ideal agent due to it's diminished efficacy in acidic vaginal pH and in the presence of blood. Chlorhexidine gluconate, on the other hand, has demonstrated superior disinfectant properties in several clinical trials, as compared to povidone iodine. In this randomized, comparator controlled, study the investigators will be comparing chlorhexidine gluconate vs povidone iodine for intrapartum vaginal preparation in women undergoing non-emergent cesarean delivery.


Options:
A: Inclusion Criteria:

* Females aged 18-50 years
* The study will be offered to women at \> 24 weeks gestation who are undergoing nonemergent cesarean delivery with ruptured amniotic membranes.
* All patients undergoing cesarean delivery with ruptured amniotic membranes.

Exclusion Criteria:

* Minors
* Emergent cesarean delivery.
* No ruptured membranes.
* Allergy to chlorhexidine or povidone-iodine.
B: Inclusion Criteria:

* Patients at Richmond University Medical Center that have a non-emergent cesarean delivery

Exclusion Criteria:

* Emergent cesarean delivery, less than 18 years of age, chorioamnionitis before randomization, intrapartum fever prior to randomization, or known or suspected allergy to chlorhexidine or iodine.
C: Inclusion Criteria:

* cesarean delivery
* age 18-65
* ability to consent in English or Spanish

Exclusion Criteria:

* inability or unwillingness to consent to study participation in English or Spanish
* current incarceration
* pre-operative diagnosis of chorioamnionitis
* perceived inability to complete follow up for data collection
* any prior known allergy or adverse reaction to either study preparation
D: Inclusion Criteria:

* Women undergoing cesarean delivery at Barnes-Jewish Hospital.

Exclusion Criteria:

* Inability to obtain consent; allergy to chlorhexidine, alcohol, iodine, shellfish; and evidence of infection adjacent to operative site.

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Early Progressive Feeding in Human-Milk Fed Extremely Preterm Infants: A Randomized Trial
Brief Summary: To test the hypothesis that progressive feeding without minimal enteral feeding (MEF) compared to progressive feeding preceded by a 4-day course of MEF will result in an increased number of days alive on full enteral feeding in the first 28 days after birth in extremely preterm infants receiving human milk.


Options:
A: Inclusion Criteria:

* Preterm infants ≦ 34 weeks gestational age and birth weight below 1500 gm and who survive to NICU are eligible for the trial.

Exclusion Criteria:

* severe asphyxia (stage III),
* fetal chromosomal anomalies,
* cyanotic congenital heart disease,
* congenital intestinal atresia, gastroschisis, omphalocele, active upper gastric intestinal bleeding,
* lacking/refused of parental consent,
* those who are fasted for \>3 weeks during the study period.
B: Inclusion Criteria:

* Preterm newborns admitted to the neonatal intensive care units with a birth weight 700-1500 g and who survive more than 3 days

Exclusion Criteria:

* Chromosomal anomalies.
* Major congenital anomalies (complex cardiac anomalies, congenital hydrocephalus, renal dysplasia)
* Congenital (e.g. jejunal atresia) and acquired (e.g. GI perforation) gastrointestinal pathology precluding oral feed and/or requiring major surgical or medical intervention
* Parental refusal
* Prior enrollment into a conflicting clinical trial
C: Inclusion Criteria:

* admission to the NICU within 48 hours with gestational age between 22.0 and 28.6 weeks

Exclusion Criteria:

* small for gestational age (\<10th percentile birthweight), major congenital or chromosomal anomalies, and infants with terminal illness in which decision to withhold or limit support have been made
D: Inclusion Criteria:

* gestational age≤32 weeks and birthweight ≤1250 gr, and \<48 hours postnatal age

Exclusion Criteria:

* Major congenital and/or chromosomal anomaly, Cyanotic congenital heart disease, Asphyxiated birth with pH \<7.0 and base deficit ≥16mmol/l Severe cardiopulmonary compromise or multiorgan failure Twin-twin transfusion, Those died in postnatal 5 days of age

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect of Low Calorie Sweetener Consumption on Body Weight, Body Composition, Appetite, and Energy Intake
Brief Summary: The aim of this study will be to compare the effects of daily consumption of aspartame, rebaudioside a, saccharin, sucralose, and sucrose on body weight and composition in a standardized protocol. The investigators hypothesize that individual low calorie sweeteners (consumed in a beverage) differ from each other in promoting weight loss and decreased fat mass (without energy restriction or dietary guidance) based on their chemical structure.


Options:
A: Postmenopausal women ages 50 to 79.
B: Inclusion Criteria:

* BMI between 25-40 kg/M2
* Non or rare users of LCS
* Willing to consume large volumes of beverages daily

Exclusion Criteria:

* Weight change \> 3kg in the last year
* Plan to initiate a new diet plan in the next 6 months
* Exhibit eating restraint
* Pregnant/lactating
C: Inclusion Criteria:

* BMI between 25 kg /m² to 36 kg / m², with low intensity physical activities and consumers of at least 3 portions of artificially sweetened beverages per week

Exclusion Criteria:

* students with hyper or hypothyroidism, pregnant women and those who perform high to moderate physical activities
D: Inclusion Criteria:

* Female
* BMI 30-35 kg/m²
* at least one period of dietary restriction of 4 weeks or more in the last 24 months

Exclusion Criteria:

* dislike of popular sweet carbonated drinks
* dieting during the last month
* history of diabetes
* having an eating disorder
* depression,
* being a smoker
* pregnant
* lactating,
* wearing a pacemaker
* currently taking medication for mood or thyroid disorders

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Effects of a Mindfulness Intervention Delivered Within Diabetes Education on Diabetes-related Outcomes in Military Veterans
Brief Summary: The purpose of this study is to see if adding Mindfulness training to diabetes education reduces feelings of stress and makes it easier to adhere to healthy behaviors that improve diabetes outcomes (such as hemoglobin A1c).


Options:
A: Inclusion Criteria:

* BMI\>30;
* Written and informed consent to participate; 4) being technology friendly to use wearable devices.

Exclusion Criteria:

* other psychiatric disturbances (diagnosed according to DSM 5 criteria);
* other medical conditions not related to obesity that could compromise participation at the study.
B: Inclusion Criteria:

* Adult aged between 18 and 65 years
* Obese (BMI \>= 30)
* Recruited from the nutrition pole of Ambroise Paré Hospital
* Diagnosed with Binge-Eating Disorder (BED) according to DSM5 criteria
* Informed consent provided during inclusion interview

Exclusion Criteria:

* Already participating in a clinical trial
* Bariatric surgery patients (except for gastric band removed at least 3 years before)
* Planned bariatric surgery
* Central obese (genetic)
* Pregnant women
* No internet access at home
* Difficulties to understand French language
* Patients under social protection
* Cognitive dysfunctions in understanding simple guidelines provided by the paramedical staff (e.g., diet or exercise guidelines)
* Auditory disorders not allowing to hear audio files
* Blurred vision not allowing to use Internet
C: Inclusion Criteria:

* Referral to DSME class at VA Pittsburgh Healthcare System University Drive Campus (VAPHS UD)
* Diagnosis of type 1 or type 2 diabetes
* Hemoglobin A1C \>7.0%
* Problem Areas in "Diabetes Scale (PAID) -5" score =/ \>3 or "Diabetes Distress Scale -2" =/\>2 score indicating the presence of Diabetes-related Distress

Exclusion Criteria:

* Documented cognitive impairment that would interfere with the ability to comprehend the informed consent and actively participate in the study
* Previous attendance of VA DSME class within the past 12 months
* Currently active mindfulness practice
D: Inclusion Criteria:

* The inclusion criteria included type 2 diabetes (as defined by the American Diabetes Association), a baseline glycosylated hemoglobin (HbA1c) value of 7-9%, and no previous exercise training in the past 6 months. All participants were free from diabetic nephropathy, diabetic retinopathy, severe diabetic neurophathy, severe cardiovascular and cerebrovascular diseases.

Exclusion Criteria:

* Participants were excluded if they dropped out or completed less than 80% of the training schedule.

Answer: C